Results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs), were reported by University of Colorado Cancer Center researchers at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO). The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials ...
Read MoreYou have just read an article categorized health
titled Results from the Phase I Trial of OMP-54F28 Reported.
Written by:
editor - Sunday, June 1, 2014
There are currently no comments for "Results from the Phase I Trial of OMP-54F28 Reported"
Post a Comment